UK-based vaccine maker Acambis has ousted its CEO and CFO and announced plans to lay off 15 percent of its staff in a restructuring triggered by its failure to land a big contract from the U.S. government. CEO Gordon Cameron is being replaced by Ian Garland, the former finance chief at Arrow Therapeutics, which was acquired recently by AstraZeneca [1]. That connection has raised speculation that Acambis could be sold or merged into another developer. Investors and analysts generally cheered the news, helping buoy the company's stock price this morning.
- check out the release [2] on the restructuring
- here's the report [3] on Acambis from The Independent
Related Articles:
Acambis shares plunge after U.S. nixes contract. Report [4]
Acambis completes vaccine BLA. Report [5]
Links:
[1] http://www.fiercebiotech.com/story/astrazeneca-announces-restructuring-and-buyout/2007-02-01
[2] http://www.fiercebiotech.com/node/5956
[3] http://news.independent.co.uk/business/news/article2338457.ece
[4] http://www.fiercebiotech.com/story/acambis-shares-plunge-after-u.s.-nixes-contract/2006-11-14
[5] http://www.fiercebiotech.com/story/spotlight-acambis-completes-vaccine-bla/2006-04-19